Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Targeted anticancer agent advances into clinical development
February 24th, 2005
AEterna Zentaris, Inc., (AEZ; AEZS) announced the initiation of a company-sponsored phase I dose-ranging study for its targeted anticancer agent AN-152, a novel cytotoxic conjugate that has the potential to selectively and specifically target certain types of cancer cells that express Luteinizing Hormone Releasing Hormones (LHRH) receptors (LHRH receptor positive tumors) and thereby may offer a better safety and efficacy profile as compared to the cytotoxic agent alone. The phase I study, which will be conducted at university clinics in Gottingen and Frankfurt/Main in Germany, will evaluate the safety (including maximum tolerated dose and dose-limiting toxicity) and...
Source: Women's Health Weekly (2005-02-24)
|
